Biopharma, PBMs battle over HHS drug pricing blueprint

Trade associations representing drug manufacturers, PBMs, hospitals, insurance companies and pharmacies presented drastically differing diagnoses of, and prescriptions for the U.S. drug market in response to the Trump administration’s request for comments about its drug pricing blueprint. The comment period ends July 16.

None of the comments from trade

Read the full 485 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE